Recorna (Guangzhou) Biotechnology Co., Ltd, a pioneering RNA editing therapy startup based in China, has entered into a strategic partnership with Starna Therapeutics, an mRNA specialist based in Suzhou. This alliance aims to combine their expertise to delve into the research and application of RNA gene editing drugs for lung diseases, with no financial details disclosed.
The collaboration will leverage Starna’s proprietary STAR LNP delivery technology platform to precisely deliver Recorna’s MINIC RNA-based gene editing drugs to the lungs. The partnership will focus on jointly screening pre-clinical candidate molecules and progressing them towards clinical development.
Unlike conventional liver-targeted LNP systems, Starna’s STAR LNP technology is designed to efficiently deliver small nucleic acids to the lungs, enabling precise gene editing while circumventing off-target toxicity. Recorna’s MINIC RNA editing platform specializes in precise single-point editing at the RNA level using small nucleotide drugs. This approach offers flexible and reversible regulation of gene expression and function, achieving multifaceted RNA regulation with safer and more diverse therapeutic characteristics.- Flcube.com
